Jubilant Pharmova Limited (IN:JUBLPHARMA)
:JUBLPHARMA
Want to see IN:JUBLPHARMA full AI Analyst Report?
Top Page
Jubilant Pharmova Limited
(JUBLPHARMA)
Select Model
Select Model
Rating:56Neutral
Price Target:
₹1,036.00
▼(-1.90% Downside)
Action:Reiterated
Date:05/25/26
The score is primarily held back by inconsistent profitability and weak free-cash-flow reliability alongside a modest uptick in leverage. Technicals are supportive with price above key moving averages and positive MACD, but elevated stochastic suggests near-term overbought risk. Valuation is a headwind given the high P/E and low dividend yield.
Positive Factors
Diversified business model
Jubilant's mix across specialty finished drugs, CDMO, APIs and radiopharma provides multiple, structurally different revenue streams. This diversification reduces dependency on any single market cycle, supports cross-segment utilisation of manufacturing assets and underpins steady demand over medium term.
Negative Factors
Erratic free cash flow
Highly variable free cash flow undermines the company's ability to consistently deleverage, invest in growth or return capital. Recurrent negative FCF in recent years implies working-capital swings or high reinvestment needs, increasing financing risk and limiting strategic optionality over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified business model
Jubilant's mix across specialty finished drugs, CDMO, APIs and radiopharma provides multiple, structurally different revenue streams. This diversification reduces dependency on any single market cycle, supports cross-segment utilisation of manufacturing assets and underpins steady demand over medium term.
Read all positive factors
Jubilant Pharmova Limited (JUBLPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹160.20B
Dividend Yield0.46%
Average Volume (3M)7.42K
Price to Earnings (P/E)32.5
Beta (1Y)1.06
Revenue Growth14.45%
EPS Growth-52.50%
CountryIN
Employees5,399
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)30.16
Shares Outstanding159,281,140
10 Day Avg. Volume4,911
30 Day Avg. Volume7,424
Financial Highlights & Ratios
PEG Ratio-0.62
Price to Book (P/B)1.82
Price to Sales (P/S)1.56
P/FCF Ratio-29.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)45.25
Revenue Forecast (FY)₹91.26B
Jubilant Pharmova Limited Business Overview & Revenue Model
Company Description
Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages i...
How the Company Makes Money
Jubilant Pharmova makes money through multiple business lines that generate revenue primarily from (1) selling finished pharmaceutical products, (2) providing contract manufacturing and development services, and (3) supplying pharmaceutical ingred...
Jubilant Pharmova Limited Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
58
Neutral
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 76.18B | 82.80B | 72.34B | 67.03B | 62.82B | 61.30B |
| Gross Profit | 42.43B | 24.94B | 46.99B | 43.52B | 42.00B | 46.42B |
| EBITDA | 12.02B | 12.60B | 10.48B | 7.93B | 6.46B | 10.66B |
| Net Income | 4.78B | 3.98B | 8.39B | 771.00M | -610.00M | 4.14B |
Balance Sheet | ||||||
| Total Assets | 135.21B | 155.23B | 127.56B | 115.48B | 111.57B | 99.91B |
| Cash, Cash Equivalents and Short-Term Investments | 6.23B | 12.68B | 10.89B | 9.56B | 10.15B | 9.86B |
| Total Debt | 28.83B | 36.15B | 27.31B | 36.64B | 36.77B | 31.92B |
| Total Liabilities | 69.50B | 84.27B | 65.18B | 61.27B | 57.65B | 46.74B |
| Stockholders Equity | 65.92B | 70.93B | 62.55B | 54.34B | 53.99B | 53.19B |
Cash Flow | ||||||
| Free Cash Flow | -3.71B | -4.36B | -435.00M | 736.00M | -1.54B | 2.38B |
| Operating Cash Flow | 3.69B | 10.13B | 10.72B | 9.71B | 6.61B | 8.38B |
| Investing Cash Flow | -6.31B | -12.85B | 4.88B | -6.08B | -5.44B | -3.80B |
| Financing Cash Flow | -1.84B | 3.33B | -14.53B | -4.33B | -1.57B | -325.99M |
Jubilant Pharmova Limited Technical Analysis
Positive
1056.10
Price Trends
907.83
Positive
937.73
Positive
1017.91
Negative
Market Momentum
28.48
Negative
65.59
Neutral
65.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLPHARMA, the sentiment is Positive. The current price of 1056.1 is above the 20-day moving average (MA) of 976.76, above the 50-day MA of 907.83, and above the 200-day MA of 1017.91, indicating a neutral trend. The MACD of 28.48 indicates Negative momentum. The RSI at 65.59 is Neutral, neither overbought nor oversold. The STOCH value of 65.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JUBLPHARMA.
Jubilant Pharmova Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹127.15B | 18.41 | ― | 0.56% | 6.91% | 16.04% | |
74 Outperform | ₹106.28B | 15.54 | ― | 0.41% | 4.88% | 66.43% | |
69 Neutral | ₹213.41B | 18.14 | ― | 0.08% | 36.98% | 39.94% | |
66 Neutral | ₹186.24B | 18.85 | ― | 0.24% | 19.73% | 18.17% | |
56 Neutral | ₹160.20B | 32.46 | ― | 0.46% | 14.45% | -52.50% | |
54 Neutral | ₹255.97B | 28.73 | ― | ― | 11.99% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:JUBLPHARMA
Jubilant Pharmova Limited
1,005.75
-110.08
-9.87%
IN:ALIVUS
Glenmark Life Sciences Limited
1,035.95
-63.60
-5.78%
IN:GRANULES
Granules India Limited
751.60
233.34
45.02%
IN:NEULANDLAB
Neuland Laboratories Ltd.
16,634.05
5,317.57
46.99%
IN:STAR
Strides Pharma Science Ltd
1,153.05
450.17
64.05%
IN:WOCKPHARMA
Wockhardt Limited
1,575.35
241.15
18.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.